In this issue:
Everolimus to overcome resistance to endocrine treatment
The bevacizumab debate
The effect of bisphosphonates on the rate of pCR
HER2/neu-positive breast cancer and trastuzumab
Predictors of AI discontinuation
CBT for hot flushes post breast cancer therap
Please login below to download this issue (PDF)